Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2A | Q9UQM7 | 4/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.75 |
| ▸ | TTR | P02766 | 3/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.71 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.71 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.71 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.71 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.71 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.71 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.71 |
| ▸ | ALB | P02768 | 1/20 | 0.71 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.71 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.71 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.71 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.71 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.71 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4',5-Dihydroxy-Diclofenac SCHEMBL7162002 | 0.90 | CAMK2A (0.81) | CAMK2APTGS2TTRPTGS1ABCB11 | |
| SCHEMBL1031733 | 0.86 | PTGS2 (1.00) | CAMK2APTGS2TTRPTGS1ABCB11 | |
| SCHEMBL10796562 | 0.86 | CAMK2A (0.75) | CAMK2APTGS2TTRPTGS1ABCB11 | |
| SCHEMBL23691079 | 0.86 | TTR (0.76) | CAMK2APTGS2TTRPTGS1ABCB11 | |
| SCHEMBL6036623 | 0.83 | PTGS2 (0.72) | CAMK2APTGS2TTRPTGS1ABCB11 | |
| Diclofenac SCHEMBL2799 | 0.83 | PTGS2 (1.00) | CAMK2APTGS2TTRPTGS1ABCB11 | |
| Diclofenac SCHEMBL29354260 | 0.83 | PTGS2 (1.00) | CAMK2APTGS2TTRPTGS1ABCB11 | |
| Diclofenac SCHEMBL996716 | 0.83 | PTGS2 (1.00) | CAMK2APTGS2TTRPTGS1ABCB11 | |
| SCHEMBL7165893 | 0.82 | PTGS2 (0.70) | CAMK2APTGS2TTRPTGS1ABCB11 | |
| Diclofenac SCHEMBL3184302 | 0.82 | PTGS2 (0.97) | CAMK2APTGS2TTRPTGS1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299450-A1 | USES OF AMPHIPHILES IN IMMUNE CELL THERAPY AND COMPOSITIONS THEREFOR | Elicio Therapeutics, Inc. | 2024-09-12 | — | — | US | claimed |
| CN-117766159-A | Non-steroidal anti-inflammatory drug and liver toxicity risk assessment method of metabolite thereof based on network architecture analysis | 重庆医科大学 | 2024-03-26 | — | — | CN | claimed |
| EP-4304638-A1 | USES OF AMPHIPHILES IN IMMUNE CELL THERAPY AND COMPOSITIONS THEREFOR | Elicio Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| WO-2022192524-A1 | USES OF AMPHIPHILES IN IMMUNE CELL THERAPY AND COMPOSITIONS THEREFOR | Elicio Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | claimed |
| EP-4735027-A1 | GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY | Pluri Biotech Ltd. (IL) | 2026-05-06 | — | — | EP | disclosed |
| US-20260071180-A1 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | PLURI BIOTECH LTD (IL) | 2026-03-12 | — | — | US | disclosed |
| US-20260062672-A1 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | PLURI BIOTECH LTD (IL) | 2026-03-05 | — | — | US | disclosed |
| US-20250388875-A1 | BIOCATALYTIC TECHNIQUES | HYPHA DISCOVERY LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| US-20250290039-A1 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | PLURI BIOTECH LTD (IL) | 2025-09-18 | — | — | US | disclosed |
| US-20250288667-A1 | GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY | PLURI BIOTECH LTD (IL) | 2025-09-18 | — | — | US | disclosed |
| US-12410411-B2 | Biocatalytic techniques | HYPHA DISCOVERY LIMITED (GB) | 2025-09-09 | — | — | US | disclosed |
| EP-4572789-A1 | GENETICALLY ENGINEERED PLACENTAL MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | Pluri Biotech Ltd. (IL) | 2025-06-25 | — | — | EP | disclosed |
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-20080045564-A1 | QUININE PRODUCTS, METHOD OF MANUFACTURE, METHOD OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080039492-A1 | Quinine products, method of manufacture, and method of use | MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION | 2008-02-14 | — | — | US | disclosed |
| WO-2008013773-A2 | QUININE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2004091522-A2 | METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| US-6355680-B1 | BLOCKING REACTION OF GLUCOSE AND ALBUMIN | EXOCELL, INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071180-A1 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | CD74, CD4, IL2RA | CAMK2A 1568/4885PTGS2 1731/4885TTR 2363/4885 |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | CAMK2A 2988/4885PTGS2 2067/4885TTR 3/4885 |
| US-20240299450-A1 | USES OF AMPHIPHILES IN IMMUNE CELL THERAPY AND COMPOSITIONS THEREFOR | CD4, CD74, CD47 | CAMK2A 3082/4885PTGS2 4065/4885TTR 3319/4885 |
| US-20250388875-A1 | BIOCATALYTIC TECHNIQUES | CYP2C9, CYC1, CYBA | CAMK2A 3725/4885PTGS2 2106/4885TTR 878/4885 |
| US-20260062672-A1 | GENETICALLY ENGINEERED PLACENTAL MUCOSALASSOCIATED INVARIANT T (MAIT) CELLS AND USES THEREOF | CD4, CD74, IL2RA | CAMK2A 1137/4885PTGS2 1722/4885TTR 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.